SCHEMBL16396358

SCHEMBL16396358

C=Cc1ccc(CC(=O)O)c([N+](=O)[O-])c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
ALDH5A1 P51649 1/20 0.41
ABAT P80404 1/20 0.41
PDK1 Q15118 1/20 0.40
HCAR3 P49019 1/20 0.38
VCAM1 P19320 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
SNCA P37840 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CASP6 P55212 1/20 0.36
AKR1B1 P15121 1/20 0.36
SRC P12931 1/20 0.36
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396357 1.00 CYP1A2 (0.63) CYP1A2ALDH5A1ABATPDK1HCAR3
SCHEMBL6355401 0.86 CYP1A2 (0.65) CYP1A2ALDH5A1ABATPDK1VCAM1
SCHEMBL16954587 0.81 PDK1 (0.48) CYP1A2ALDH5A1ABATPDK1VCAM1
SCHEMBL16410287 0.80 CYP1A2 (0.41) CYP1A2PDK1ALDH1A1MAPTLMNA
SCHEMBL16951900 0.78 ALDH3A1 (0.44) CYP1A2ALDH5A1ABATPDK1VCAM1
SCHEMBL865986 0.78 CYP1A2 (1.00) CYP1A2ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL3291900 0.78 CYP1A2 (1.00) CYP1A2ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL15272523 0.78 CYP1A2 (0.71) CYP1A2PDK1ALDH1A1MAPTSNCA
SCHEMBL1224216 0.76 CYP1A2 (0.69) CYP1A2PDK1MAPTSNCAMAOA
SCHEMBL442788 0.76 CYP1A2 (0.69) CYP1A2PDK1VCAM1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CYP1A2 402/4885ALDH5A1 3001/4885ABAT 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.